OBJECTIVE: The impact of CYP2A6*21 (K476R) on in vivo nicotine metabolism and disposition was investigated. METHODS: A two-step allele-specific PCR assay was developed to detect the 6573A>G single nucleotide polymorphism (SNP) in CYP2A6*21. Nicotine metabolism phenotypes from a previously described intravenous labeled nicotine and cotinine infusion study [1] was used to assess the impact of CYP2A6*21. Genomic DNA samples from 222 (111 monozygotic and dizygotic twin pairs) Caucasian subjects were genotyped for CYP2A6 alleles (CYP2A6*1X2, -*1B, -*2, -*4, -*7, -*9, -*10, -*12, and -*21). The pharmacokinetic parameters were compared between individuals with no detected CYP2A6 variants (CYP2A6*1/*1, n = 163) and individuals heterozygous for the CYP2A6*21 allele (CYP2A6*1/*21, n = 9). RESULTS: The frequency of the CYP2A6*21 allele was found to be 2.3% in Caucasians (n = 5/222 alleles, evaluated in one twin from each twin pair). In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively. CONCLUSIONS: CYP2A6*21 does not have a detectable impact on nicotine metabolism in vivo. Our data suggest that CYP2A6*21 may not be important for future studies of nicotine metabolism and the resulting impacts on smoking behaviors.
OBJECTIVE: The impact of CYP2A6*21 (K476R) on in vivo nicotine metabolism and disposition was investigated. METHODS: A two-step allele-specific PCR assay was developed to detect the 6573A>G single nucleotide polymorphism (SNP) in CYP2A6*21. Nicotine metabolism phenotypes from a previously described intravenous labeled nicotine and cotinine infusion study [1] was used to assess the impact of CYP2A6*21. Genomic DNA samples from 222 (111 monozygotic and dizygotic twin pairs) Caucasian subjects were genotyped for CYP2A6 alleles (CYP2A6*1X2, -*1B, -*2, -*4, -*7, -*9, -*10, -*12, and -*21). The pharmacokinetic parameters were compared between individuals with no detected CYP2A6 variants (CYP2A6*1/*1, n = 163) and individuals heterozygous for the CYP2A6*21 allele (CYP2A6*1/*21, n = 9). RESULTS: The frequency of the CYP2A6*21 allele was found to be 2.3% in Caucasians (n = 5/222 alleles, evaluated in one twin from each twin pair). In vivo pharmacokinetic parameters, such as nicotine clearance (1.32+/-0.37 vs. 1.18+/-0.20 L/min), fractional clearance of nicotine to cotinine (1.02+/-0.36 vs. 0.99+/-0.23 L/min), nicotine half-life (111+/-37 vs. 116+/-29 min), and the trans-3'-hydroxycotinine to cotinine ratio (1.92+/-1.0 vs. 1.55+/-0.58) indicated no substantial differences in nicotine metabolism between those without the variant (CYP2A6*1/*1, n = 163) and those with the variant (CYP2A6*1/*21, n = 9), respectively. CONCLUSIONS:CYP2A6*21 does not have a detectable impact on nicotine metabolism in vivo. Our data suggest that CYP2A6*21 may not be important for future studies of nicotine metabolism and the resulting impacts on smoking behaviors.
Authors: J O'Loughlin; G Paradis; W Kim; J DiFranza; G Meshefedjian; E McMillan-Davey; S Wong; J Hanley; R F Tyndale Journal: Tob Control Date: 2004-12 Impact factor: 7.552
Authors: Gary E Swan; Neal L Benowitz; Peyton Jacob; Christina N Lessov; Rachel F Tyndale; Kirk Wilhelmsen; Ruth E Krasnow; Mary R McElroy; Sharyn E Moore; Michelle Wambach Journal: Twin Res Date: 2004-10
Authors: Gary E Swan; Neal L Benowitz; Christina N Lessov; Peyton Jacob; Rachel F Tyndale; Kirk Wilhelmsen Journal: Pharmacogenet Genomics Date: 2005-02 Impact factor: 2.089
Authors: Joseph F Solus; Brenda J Arietta; James R Harris; David P Sexton; John Q Steward; Chara McMunn; Patrick Ihrie; Janelle M Mehall; Todd L Edwards; Elliott P Dawson Journal: Pharmacogenomics Date: 2004-10 Impact factor: 2.533
Authors: Joseph Bloom; Anthony L Hinrichs; Jen C Wang; Linda B von Weymarn; Evan D Kharasch; Laura J Bierut; Alison Goate; Sharon E Murphy Journal: Pharmacogenet Genomics Date: 2011-07 Impact factor: 2.089
Authors: Katrina G Claw; Julie A Beans; Seung-Been Lee; Jaedon P Avey; Patricia A Stapleton; Steven E Scherer; Ahmed El-Boraie; Rachel F Tyndale; Deborah A Nickerson; Denise A Dillard; Kenneth E Thummel; Renee F Robinson Journal: Nicotine Tob Res Date: 2020-05-26 Impact factor: 4.244
Authors: Jill C Mwenifumbo; Qian Zhou; Neal L Benowitz; Edward M Sellers; Rachel F Tyndale Journal: Pharmacogenomics Date: 2010-02 Impact factor: 2.533
Authors: Taraneh Taghavi; Christopher A Arger; Sarah H Heil; Stephen T Higgins; Rachel F Tyndale Journal: J Pharmacol Exp Ther Date: 2017-11-20 Impact factor: 4.030
Authors: Ruth E Krasnow; Lisa M Jack; Christina N Lessov-Schlaggar; Andrew W Bergen; Gary E Swan Journal: Twin Res Hum Genet Date: 2012-10-19 Impact factor: 1.587